Aug 31 – Sep 6, 2026 · 3 new studies, 2 reviews · Orthopaedic Oncology archive · All weeks
The new Orthopaedic Oncology research The Reduction sent the week of Aug 31 – Sep 6, 2026, with the week’s most recent reviews, each with a one-line summary.
Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
A 36-patient series shows 3D specimen scanning and virtual margin mapping is a scalable workflow that enables AR-guided re-resection and dynamic margin visualization in musculoskeletal oncology.
What Is the 5-year Survival of Patients With or Without Surgery in Spinal Metastatic Disease?
In a large registry, only about 9% of spinal metastasis patients survived 5 years, with SORG and NESMS scores remaining strong predictors of long-term survival to guide surgical decision-making.
A 10-year Thai national cohort of over 16,000 spinal metastasis surgeries found rising surgical volume and comorbidity burden, with a 12.8% complication rate and 4.2% in-hospital mortality.
This review outlines how radiography, CT, MRI, and PET/CT each contribute to Ewing sarcoma diagnosis, staging, and treatment response assessment, with radiomics/AI emerging as promising tools for risk stratification.
Whole body imaging in musculoskeletal oncology: when, why, and how.
This review outlines when and how whole-body imaging techniques (MRI, CT, PET-CT) are used in musculoskeletal oncology for assessing tumor burden, metastases, and syndromic surveillance.
← Week of Aug 24–30, 2026Week of Sep 14–20, 2026 →
Home · All weeks · Archive · Subscribe · FAQ
© 2026 The Reduction